Umlaut.bio
Berlin, Germany· Est. 2021
Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.
Private Company
Total funding raised: $2.5M
About
Decoding RNA modifications to revolutionize cancer and inflammation treatment. Umlaut.bio GmbH is a pioneering biotech company focused on developing first-in-biology therapeutic molecules to modify tRNA and target cancers and inflammatory diseases.
Small Molecules
Funding History
1Total raised:$2.5M
Seed$2.5MJun 15, 2022